US set to offer monkeypox vaccines in states with high case rates


The move comes after pressure from states, who have been pushing the Administration to release more doses of monkeypox vaccine from the Strategic National Stockpile which is managed by the Office of the Assistant Secretary for Preparedness and Response at the Department of Health and Human Services.

The plan will allocate doses based on case rates in a state, focusing on men who have sex with men and their partners, as well as anyone who thinks they might have been recently exposed to the virus, according to two sources familiar with the government’s plans who were not authorized to speak with reporters.

Currently, 10 states would be considered to be in the first tier for priority in ordering vaccines.

The plans are expected to be officially announced later Tuesday evening.

They come in the middle of Pride month, a month filled with parties celebrating gender and sexual diversity, and a season that many in public health have worried will only fuel the spread of the monkeypox virus which is spread by close contact, including sex.

The vaccination plan may require the US to use two different types of vaccines.

The first is a newer, modern vaccine called Jynneos which is manufactured by a Danish company called Bavarian Nordic. It was evaluated and developed and to treat monkeypox infection. The US currently has 64,000 doses of this vaccine in the stockpile. The government will make 56,000 of those doses available to states in phase one of the roll out. More doses of this vaccine have been ordered and are expected to be delivered later this year.

The problem is that the US may not have enough doses of Jynneos to vaccinate all who might need it, so public health officials are also considering whether to use a second older type of vaccine called ACAM. The ACAM vaccine was developed to treat smallpox. It’s given by using a two pronged needle that’s repeatedly dipped into the vaccine and used to prick the skin on the upper arm, causing a small sore or “pock” to form.

“It’s a very kind of like, old-school technology that basically I don’t know any clinicians that actually know how to do that. So it’s actually very difficult to roll out because you have to train people in a new vaccine methodology,” said Dr. Jay Varma, professor and director of the Cornell Center for Pandemic Prevention and Response in New York City.

The other complications is that the ACAM vaccine uses a live, but weakened version of a virus to inoculate a person.

“It’s presumed not to be safe to be able to be used in people with HIV,” Varma said. The primary risk group for monkeypox—men who have sex with men—also has high rates of HIV infection.

Quoted from Various Sources

Published for: 533Soft